CACI CACI International Inc

CACI International Inc (NYSE:CACI) announced today that it has been awarded a prime position on the Engineering-Technical and Logistics Domains of the Omnibus Program Engineering and Technical Support (OPETS) contract. CACI will support development and fielding of chemical and biological defense materiel for the Department of Defense (DoD) Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). With a ceiling value of approximately $40 million for each of the two domains, the five-year (three-year base period plus a two-year option period) indefinite delivery/indefinite quantity contract expands CACI’s presence in its C4ISR (command, control, communications, computers, intelligence, surveillance, and reconnaissance) and logistics and material readiness markets.

The JPEO-CBD is responsible for advanced research, development, acquisition, fielding, and lifecycle support of chemical and biological detection and reconnaissance systems, protection and decontamination systems, information management systems, medical technology, and installation and force protection systems for DoD missions overseas and in the U.S. To help keep Armed Forces personnel safe from chemical and biological threats, CACI will compete for task orders to provide JPEO-CBD with subject matter experts on chemical and biological defense, the development of technical drawings, configuration management, and logistics analysis and risk management.

CACI has extensive C4ISR experience that includes a long history of support on programs such as the U.S. Army’s Strategic Services Sourcing (S3) and Technical Engineering Support Services contracts as well as ongoing support of development work for the Army’s Stryker Nuclear Biological Chemical Reconnaissance Vehicle.

John Mengucci, CACI Chief Operating Officer and President of U.S. Operations, said, “Our extensive involvement in wide-ranging projects in the C4ISR and logistics arenas will be directly relevant in ensuring the success of the Joint Program Executive Office for Chemical and Biological Defense’s mission. We look forward to providing the critical expertise required to help keep our Armed Forces out of harm’s way.”

According to CACI President and Chief Executive Officer Dan Allen, “We are excited for this new contract award with the Joint Program Executive Office and their confidence in CACI to support their critical mission developing chemical and biological defense solutions for our military. Our global presence and proven ability to rapidly deploy the technology and solutions required to support the DoD’s high priority missions are enabling CACI to partner effectively with agencies throughout the defense community and are key elements of our strategy to grow our business.”

CACI provides information solutions and services in support of national security missions and government transformation for Intelligence, Defense, and Federal Civilian clients. A member of the Fortune 1000 Largest Companies and the Russell 2000 Index, CACI provides dynamic careers for approximately 14,900 employees working in over 120 offices worldwide.

There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.

CACI-Contract

Grafico Azioni CACI (NYSE:CACI)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni CACI (NYSE:CACI)
Storico
Da Lug 2023 a Lug 2024